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The potential of growth factors to stimulate tissue healing through the enhancement of cell proliferation, mi-
gration, and differentiation is undeniable. However, critical parameters on the design of adequate carriers, such
as uncontrolled spatiotemporal presence of bioactive factors, inadequate release profiles, and supraphysiological
dosages of growth factors, have impaired the translation of these systems onto clinical practice. This review
describes the healing cascades for bone, cartilage, and osteochondral interface, highlighting the role of specific
growth factors for triggering the reactions leading to tissue regeneration. Critical criteria on the design of carriers
for controlled release of bioactive factors are also reported, focusing on the need to provide a spatiotemporal
control over the delivery and presentation of these molecules.
Introduction
The recreation and maintenance of functionallyviable tissues using tissue engineering (TE) approaches
incorporating controlled release functionalities is quite chal-
lenging due to the fact that cells respond to a wide array of
structural, biochemical, and temporal cues in a microenvi-
ronment, which is difficult to simulate.1 These stimuli work
in cooperation to assemble and organize cells and their re-
spective matrix into tissues. The concept of biomimicry relies
on the development of nature-inspired biomaterials aiming
for the generation of new tissues and organs. Biomimetic
approaches can be applied through different perspectives,
including tissue functionality, materials/composition, and
biological mechanisms, intervening in tissue formation, re-
modeling, and healing.2
This review will address the increasing level of complexity
and functionality in the design of TE approaches through the
spatiotemporal controlled delivery of bioactive factors from
three-dimensional (3D) constructs and their effect on the
skeletal tissue healing. It comprises the recapitulation of
native bone, cartilage, and osteochondral interface morpho-
genesis and healing; specifically, the sequence of events
leading to tissue regeneration and the key signaling mole-
cules involved in those processes. Moreover, the variables
involved in the design of controlled delivery systems for the
desired targeting tissues are also highlighted; specifically, the
presentation of the appropriate sequence, rate, and dosage of
bioactive factors in a spatiotemporal controlled manner.
Brief Recapitulation of Native Skeletal
Tissue Morphogenesis and Healing
There has been considerable interest in understanding the
signaling interplay in bone and cartilage due to their limited
ability to heal upon serious fracture or trauma. Bone is
comprised of a variety of cell populations, extracellular ma-
trix (ECM), and other proteins as well as inorganic compo-
nents that work synergistically to sustain physical forces,
molecular signals, and systemic hormone networks.3 On the
other hand, articular cartilage is a highly resilient connective
tissue that covers the surfaces at the ends of long bones.4 The
osteochondral tissue is a gradual transition from cartilage to
bone in which the key constituents of each tissue undergo an
exchange in predominance.5,6 Therefore, the treatment of
osteochondral lesions is even more problematic because
tissue damage involves two different tissues with different
intrinsic healing capabilities.7
Bone healing
Bone is distinguished from other tissues by the presence of
inorganic hydroxyapatite8 and a wide range of organic
components, mostly collagen type I. The mineral part con-
stitutes 65%–70% of the matrix, whereas the organic phase
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comprises the remaining 25%–30% of the matrix. From a
materials science perspective, bone can be considered as a
truly composite material.9 The mineralized collagen-based
ECM is the defining feature of bone, which provides its
unique biomechanical properties.10–13 Collagen type I can
initiate and orientate the growth of carbonated apatite min-
eral, controlling its size and 3D distribution.14–16 The com-
plex hierarchical structure, material properties of the
constituents, cellular organization, and molecular cues work
in concert to perform the function of bone.17 The hierarchical
geometrical structure of bone is critical, not only for the
macroscopic mechanical properties, but also for cells, which
respond to these by converting mechanical and architectural
cues into intracellular signals, which drive activities, such as
gene expression, protein production, and general phenotypic
behavior.17–22
Upon injury, bone tissue presents the ability to self-repair,
in contrast to soft tissue that heals by forming scar tissue.23,24
The vast majority of defects heals on their own or recovers
after standard orthopedic procedures.25,26 Surgical treat-
ments of bone defects typically fall into two groups: the Ili-
zarov method27 and the bone graft transplant.28 Although
the Ilizarov method—osteotomy followed by bone distrac-
tion—takes advantage of the regeneration potential of bone,
it is a highly inconvenient procedure for the patient.29 Over
the last decades, the medical field has advanced dramatically
in the understanding of tissue and organ healing and re-
pair.30 Transplantation of organs or tissues is still a common
accepted methodology to treat patients and tissue replace-
ments, such as autografts,31–33 allografts,34–36 xenografts,37–39
and graft substitutes,40–42 are clinically available therapies to
restore the tissue structure and function.43 However, the
current situation is suboptimal at best44,45 with the current
grafting methodologies presenting several and obvious lim-
itations, including lack of donors,46 donor-site morbidity,47
complicated surgical procedures,48 immune rejection,49
chronic inflammation,50 and lack of clinical predictability.51
However, extreme situations, such as compromised wound
environment,44,52 biomechanical instability,45,53 or insuffi-
cient surgical techniques,54,55 might lead to large defects with
limited intrinsic regeneration potential, often designated as
critical size defects. In these cases, complete regeneration
cannot occur.25,56
Bone metabolism is a complex process regulated by a large
number of bioactive molecules, and bone repair is, to a large
extent, a recapitulation of developmental events.57,58 During
the fracture repair process, cells progress through stages of
differentiation reminiscent of those that cells undergo during
normal fetal bone development.26 Four stages of bone repair
have been described, as shown in Figure 1: (1) immediate
postfracture (day 1–2). Trauma leads to the activation of the
local host response, with the activation and influx of in-
flammatory cells and secretion of various mediators, leading
to the formation of hematoma. This process is necessary for
the initiation of tissue repair and wound healing59; (2) in-
tramembranous ossification (days 3–5). Immune cells stim-
ulate cell division of osteochondrogenitors and fibroblast-like
cells in the cambium layer of periosteum60; (3) chondrogen-
esis (days 6–9), through the proliferation of chondrocytes
and production of cartilaginous matrix61 and; (4) endo-
chondral ossification (days 10–20), through the production of
mineralized ECM and vascularization of the tissue.62,63 Al-
though overlapping occurs, there is a temporal sequence of
maximum levels of specific growth factors (GFs) and cyto-
kines.64 One of the critical aspects for bone formation is the
formation of an extensive network of blood vessels as both
intramembranous and endochondral bone ossification occur
in close proximity to vascular ingrowth.8,65 Endochondral
ossification is the process by which mesenchymal stem
cells (MSCs) differentiate toward chondrocytes, producing a
cartilaginous template, which contributes to longitudinal
growth of the majority of bones and is gradually replaced
by bone and marrow. During this process, chondrocytes
proliferate, undergo hypertrophy, and die. The deposited
cartilage ECM is invaded by blood vessels, osteoclasts, bone
marrow MSCs (BMSCs) and osteoblasts and deposition
of mineralized ECM is initiated.66,67 On the other hand,
intramembranous ossification occurs in the absence of a
cartilage template, whereby bone develops directly from
mesenchymal progenitors.67,68
FIG. 1. Stages of bone healing upon fracture/injury, which
can be divided in five main steps: inflammation, in-
tramembranous ossification, chondrogenesis, endochondral
ossification, and remodeling. In more detail, after injury (i),
bone undergoes an induction stage where there is an influx
of inflammatory cells and occurs the formation of hematoma,
as shown in (ii). Gray areas represent necrotic bone tissue.
Afterward, during inflammation, occurs the formation of a
cartilage intermediate, as it can be observed by the gray area
in (iii). Stage (iv) represents the formation of the soft callus, in
which a chondrogenic matrix unites the defect area. From
this moment, ossification occurs and woven bone replaces
the temporary cartilaginous template through the invasion of
blood vessels (stage (v)) and finally, remodeling occurs in
step (vi) with lamellar bone promoting the union of the de-
fects and the medullar cavity being restored. Adapted from
refs.68,69 Color images available online at www.liebertpub
.com/teb
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Bone formation is comprised of series of cellular events,
which include (1) chemotaxis of osteoblast precursors to the
sites of resorption defects69,70; (2) proliferation of these pre-
cursors to form a team of osteoblasts capable of filling in
the resorption defect71,72 followed by (3) differentiation of the
preosteoblasts to form mature cells, which are responsible for
expressing the structural proteins of bone, such as collagen
type I and other functional proteins.67,73–75
Bone biochemical environment permits and promotes
cellular functions that lead to matrix production and ossifi-
cation.76 The matrix is an active and dynamic biochemical
system, including important regulatory cues to nearby cells,
affecting gene expression and changes at the cytostructural
level.76 There are several mobile (GFs, transcription factors,
and cytokines)77–83 and immobilized (collagen type I, fibro-
nectin, decorin, and biglycan)84–89 macromolecules in the
bone ECM directing bone cells behavior. Some of the most
important soluble mobile macromolecules include the
platelet-derived growth factor (PDGF),90 Bone morphoge-
netic protein (BMP),91 Insulin growth factor (IGF),92 and
transfoming growth factor (TGF).93 In addition to minerali-
zation, osteoblasts produce a matrix of proteins that not only
serve to structurally support cells, but also to provide a va-
riety of chemical cues, which regulate functionality, namely,
the ability to promote mineralization.17,94–96 The most
abundant protein is collagen type I, which besides playing
the main role in the tensile properties of bone, also contains
peptides, which cue bone cells.97 The most abundant non-
collagenous bone ECM protein is osteonectin, known for its
multiple calcium and collagen binding sites. Moreover, it has
been shown to be a potential nucleator of hydroxyapa-
tite.17,98,99 The second most abundant noncollagenous pro-
tein in bone ECM is osteocalcin, which presents affinity for
calcium/hydroxyapatite and has also been involved in the
osteoclast migration process.17,100
Inflammation is also a key component of the early re-
sponse to bone injury.101,102 Inflammatory cells are recruited
to the damaged bone and release cytokines, chemokines, and
GFs that amplify the process.103 Inflammation in the early
phase of fracture repair is associated with enhanced healing,
while chronic inflammation has a deleterious effect on
healing.3 Following implantation of materials, inflammatory
responses are also expected. The host initiates a physiological
healing reaction, consisting first of an acute inflammatory
response followed by repair processes.104,105 This inflamma-
tory stage provides the appropriate signals for the shift from
inflammation to repair and remodeling of the tissue.106–108
The extent or degree of the inflammatory response is con-
trolled by the extent of injury in the implantation procedure,
by the tissue or organ into which the device is implanted and
the extent of provisional matrix formation.107 The initial
week-long inflammatory phase of fracture healing is charac-
terized by the influx of inflammatory cells, that is, neutro-
phils, lymphocytes, and macrophages and the release of
various cytokines and GFs.109 The inflammation process
constitutes the fundamental difference between development
and regeneration.26 Therefore, modulation of inflammation
has been an increasingly used strategy to control tissue re-
generation.110 When delivering cytokines, precise spatial and
temporal control over the delivery profile is required because
both prolonging and obliterating signaling might impair bone
healing.109
There is a close inter-relationship between bone healing
and formation of the vascular compartment. The clinical
significance of angiogenesis in bone regeneration is of ut-
termost importance as an appropriate blood supply has been
recognized as an essential component of normal fracture
healing.111,112 Angiogenesis, the growth of new capillary
blood vessels from pre-existing host vasculature,113 is also
involved in the initiation of fracture healing and promotion
of endochondral and intramembranous ossification in bone
development, through blood vessel invasion of avascular
cartilage114,115 and ingress of osteoblast progenitors,111,116,117
respectively. It involves the formation of capillary networks
by endothelial cells, thereby enabling the transport of oxygen,
nutrients, and waste throughout the tissue.118 The sufficient
supply of nutrients and oxygen to the cells transplanted into
the body is indispensable for cell survival and consequent
maintenance of their biological function.119,120 Angiogenesis
is a complex process involving endothelial cell activation,121
recruitment,122 and migration 123 to sprout the neovessels to
the mural cells (pericytes or smooth muscle cells) making up
the surrounding vessel wall for stabilization.8 All vasculari-
zation processes involve a series of interactions among
cytokines, GFs, various types of cells, and enzymes.124,125
Osteoblasts and endothelial cells cross-talk and act synergis-
tically toward the formation of a mature vascular network
and for the differentiation of osteoprogenitor cells into oste-
oblast and formation of bone ECM.3,126,127
Cartilage healing
Articular cartilage is composed by a unique type of cell,
the chondrocyte, embedded within a dense ECM consisting
of 80% water, a collagen type II network, and proteogly-
cans.128,129 Although cartilage appears to be a simple an-
eural, avascular, connective tissue, there are many levels of
complexity in its composition and structure.130,131 Both cells
and matrix distribute within successive cartilage layers
identified as superficial, transitional, radial (deep zone), and
calcified zones.29 Cartilage tissue demonstrates significant
differences in cell phenotype, composition, and matrix or-
ganization along the depth of the tissue, reflecting different
biomechanical and functional requirements of different
zones.132–134
Hyaline cartilage is characterized by its high content on
proteoglycan aggrecan, which exists in the form of proteo-
glycan aggregates in association with hyaluronan (HA) and
link protein (LP). These aggregates are responsible for the
turgid nature of cartilage, providing the osmotic properties
necessary to resist compressive loads.135,136 A variety of
small leucine-rich repeat proteoglycans (SLRPs), such as
decorin,137 biglycan,137 fibromodulin,138 and lumican,139 are
also present and contribute for the maintenance of integrity
of the tissue and to modulate its metabolism.135
The most basic functions of cartilage include providing
near frictionless surface between load bearing in the joints to
allow for pain-free motion, shock-absorbance, and load dis-
tribution.140 The avascularity of articular cartilage has led to
the assertion that the tissue is immunoprivileged, whereby
the body’s immune system is limited in its ability to detect
and reject implanted tissue.141
Numerous GFs work in concert to regulate develop-
ment and homeostasis of articular cartilage throughout life,
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in particular bioactive factors from the TGF-b super-
family,142–145 Fibroblast growth factor (FGF) family,146 and
IGF-I.147–149 Architectural design for regenerative medicine
and surgery is also an adaptation of the phenomenon
observed during development and morphogenesis.150 To
properly restore the zonal structure of cartilage, phenotypi-
cal differences between chondrocyte populations and the
response of chondrocyte subpopulations to GFs and external
stimulus should be fully understood.151
Typically, chondrocytes respond to injury caused by me-
chanical insult, joint instability, and inflammatory cytokines
through matrix activation, cell proliferation, apoptosis, and
matrix destruction.152,153 The activation of chondrocytes can
result in modulation of gene expression, resulting in different
patterns of protein synthesis, fibroblast dedifferentiation,
hypertrophy, or regeneration of mature cartilage.152 The lack
of vascular supply in cartilage limits early repair responses
upon injury.150 Consequently, injury to cartilage usually
heals through a scar tissue formation mainly composed of
fibrocartilage with inferior mechanical properties and a
gradually degrading nature.4 Moreover, cartilage has a low
cell:matrix ratio and chondrocytes have a relatively low
metabolic activity limiting the tissue remodeling activity.154
Only when the injury reaches the subchondral bone, self-
healing processes are initiated by the release of mesenchymal
progenitor cells from bone marrow into the wound site.2 This
observation forms the basis of surgical repair techniques,
such as abrasion arthroplasty,155,156 drilling,157 and micro-
fracture158 to penetrate the subchondral bone. Periosteum is
also a source of cells that can differentiate into chondrocytes
and autogenous or allogeneic cell/tissue transfer via peri-
osteal grafts159,160 has been used, while other techniques
have used chondrocytes or cartilage directly. Autologous
chondrocyte transplantation involves harvesting cells from a
noninvolved area of the joint, to expand them in culture, and
then transplanting them to the area of involvement.161–163
However, these techniques present several limitations
particularly on cell and tissue availability, unwanted fi-
brocartilage formation and inadequate graft integration.164–166
Another strategy for the regeneration of articular cartilage is
mosaicplasty and it is based on the creation of multiple small
osteochondral grafts.167–170 The limiting factor of mosaicplasty
resides in the donor-site availability of grafts.
In degenerative diseases, such as osteoporosis or rheuma-
toid arthritis, the remodeling equilibrium of cartilage is dis-
rupted and the rate of collagen and proteoglycans loss from
the matrix exceeds the rate of deposition of newly synthesized
molecules.152,171,172 The upregulation of cartilage-degrading
enzymes can be caused by several factors, such as chemokines,
other inflammatory mediators, and mechanical loading.173
Although current approaches are reasonably effective in
achieving clinical endpoints of symptomatic relief, they have
not been successful at preventing future degeneration of the
repaired tissue and surrounding host environment.174 Hence,
TE is a promising approach for the regeneration of articular
cartilage as it might provide the tools to overcome the limi-
tations observed with the current treatments.175
Osteochondral regeneration
Cartilage and bone arise from a common progenitor and
exist in apposition at articular surfaces of synovial joints as
well as in the epiphyseal growth plate.176 Structurally, the
osteochondral interface is the connection between a layer of
hyaline cartilage and underlying bone and it is crucial for
load transfer between bone and cartilage.6 Moreover, it has
been shown that the osteochondral interface is critical to
maintain the integrity of cartilage by simultaneously limiting
vascular ingrowth from the subchondral bed and preventing
ectopic mineralization.177 The interface typically is charac-
terized by a decreased amount of water content and collagen
type II in comparison with the more superficial layers of
cartilage. Moreover, the collagen fiber diameter is also in-
creased and perpendicular in direction with respect to the
articulating surface.178
Osteochondral tissue is comprised of osteoblasts, osteo-
clasts, and chondrocytes, but as these phases merge, there is
an overlap in cellular function. Hence, this interface is
composed of hypertrophic chondrocytes embedded in a
mineralized cartilage matrix.5,177 While the chondral repair
mechanism relies on the intrinsic healing capabilities of
chondrocytes, osteochondral defects allow the recruitment of
progenitor cells from bone marrow to assist regeneration of
cartilage and underlying bone structure.179
Osteochondral defects penetrate through the vascularized
subchondral bone and spontaneous repair occurs as mesen-
chymal chondroprogenitor cells invade the lesion and form
cartilage. However, full-thickness defect repair is only tran-
sient. The neo-formed tissue is fibrous and enriched in col-
lagen type I and fibronectin and does not have the functional
properties of native hyaline cartilage.4,29,180
For the treatment of large osteochondral defects, one of the
options is autologous osteochondral grafts such as those
used in mosaicplasty.170,181,182 However, donor-site mor-
bidity and lack of integration can compromise long-term
graft outcomes.183 Presently, a significant barrier to clinical
translation is how to achieve functional integration of tissue-
engineered orthopedic grafts.184
The concept of osteochondral TE, a hybrid of bone and
cartilage regeneration, has attracted considerable attention,
particularly as a technique for promoting superior cartilage
integration and as a treatment for osteochondral de-
fects.179,185–196 For osteochondral scaffolds, additional design
criteria should be considered to achieve the best possible
simultaneous growth of the two independent tissues in-
volved. This may require the use of biphasic constructs with
gradients of mechanical, structural, and molecular proper-
ties.154,177,197–200 The most common approach consists in the
development of independent layers for each zone, because
chondrocytes and bone cells show distinct metabolic and
structural functionality, yet communicating and interacting
in a unique culturing system.201 The junction of two layers
has been achieved by fibrin sealant, simple press-fitting,
suturing, or external fixation.179 These scaffolds constitute
the first generation of stratified scaffolds.183 A scaffold with a
predesigned inhomogeneity can better sustain and transmit
the distribution of complex loads inherent at the multitissue
interface and several studies have reported new designs to
fulfill this request.202–206 Constructs to be used for regener-
ation of osteochondral defects may also benefit from the
application of hierarchically and structurally organized drug
delivery systems. One area of special importance in os-
teochondral graft design is the regeneration of the bone to
cartilage interface or a calcified cartilage layer between bone
SKELETAL TISSUE HEALING AND VARIABLES FOR THE DESIGN OF DELIVERY SYSTEMS 311
and cartilage regions, which is critical for graft integration
and for establishing long-term functionality.183
Signaling molecules on natural cascades of bone,
cartilage, and osteochondral formation/healing
Bone. During bone formation, mobile cues directing cell
behavior in bone can be produced by local osteoblasts or
delivery via blood stream. These GFs have indisputable roles
in osteoblast proliferation, differentiation, and subsequent
bone formation and regulation.17,207–209 These molecules act
through autocrine and paracrine signaling mechanisms to
induce the migration, proliferation, and differentiation of
osteoprogenitor cells and/or synthesis of collagen type I and
matrix apposition by mature osteoblasts.210 Upon matrix
destruction, either caused by natural bone remodeling pro-
cess or bone fracture, these factors are released to initiate
osseous healing and to maintain the cyclic anabolic and
catabolic processes that continuously remodel bone.210
The local concentration of chemical cues that can influence
bone cells increases substantially in the event of an injury.
Bone tissue injury initiates a cascade of events leading to the
migration of neutrophils, macrophages, and fibroblasts,
which subsequently express and secrete a variety of cyto-
kines and transcriptional factors, which direct migration of
MSCs, neovascularization, and remodeling/healing.17,211
Moreover, immobilized bone ECM macromolecules act as
primary chemical effectors in cell signaling and functionality.
Several bone ECM proteins contain progenitor and osteo-
blast integrin-binding sites and GF-binding sites, presenting
an obvious selection for developing scaffolds for bone.17
Many GFs, such as BMPs,212 basic FGF (bFGF),213 IGF,214
TGF-b,215 PDGF,216 and vascular endothelial growth factor
(VEGF),217 have been found to induce new bone through
their effects on the recruitment, proliferation, and differen-
tiation of bone-forming cells.218 Their role in bone morpho-
genesis and regeneration is described in Table 1 and their
expression profile is shown in Figure 2. It is likely that
multiple factors regulating distinct aspects of the regenera-
tive process can be used in parallel to affect the regeneration
of functional tissues.219
Cytokines are included in this group of factors and they
are mainly involved in systemic processes, such as host de-
fense and homeostasis, including interleukins (ILs), which
are proinflammatory molecules involved in bone resorption
and remodeling.76 Cytokines encompass a large family of
immunomodulating agents playing key roles in the cross talk
between the immune and skeletal systems.57 Bone fracture is
an injury that initiates an inflammatory response that peaks
24 h following the injury and is complete by the first week.110
During this time, a complex cascade of proinflammatory
signals and GFs are released in a temporally and spatially
controlled manner.110
Bone fracture stimulates expression of several dozen in-
flammatory cytokines, including several isoforms of ILs. IL-
1, IL-6, as well as tumor necrosis factor-alpha (TNF-a) are
shown to play a key role in initiating the repair cascade. They
have a chemotactic effect on other inflammatory cells and on
the recruitment of MSCs.220
Levels of most inflammatory mediators return to baseline
after the week-long acute inflammatory phase.109 Other rel-
evant bioactive factors acting on the morphogenesis of these
tissues include hormones known for controlling serum cal-
cium concentrations and stimulating osteoblast proliferation
and differentiation.76
During bone regeneration there is a temporal sequence of
GFs and cytokines expression.63,234,235 Angiogenic GFs are
predominantly expressed during the early phases to re-
establish vascularity, whereas osteogenic GFs are continu-
ously expressed during bone formation and remodeling.219
Numerous GFs are involved in angiogenesis, including
VEGF,236 FGF-2,237 PDGF,238 Ang-1,239 and -2,240 IGF,241
among others.124
During normal bone healing, VEGF expression was shown
to peak in early days with high expression from days 5 to 14,
while BMP expression peaked at a later time point. Since
establishment of a vascular bed is an early event that pre-
cedes the formation of bone, a similar temporal release
profile should be designed to promote bone regenera-
tion.242,243 VEGF is likely produced by inflammatory cells as
well as mesenchymal progenitors that are recruited to the
site of bone injury. VEGF expression can also be driven to
hypoxia as VEGF represents a target gene of hypoxia-in-
ducible factor.111
Despite extensive studies on the biology and delivery of
GFs, only two formulations are currently approved by the
Food and Drug Administration (FDA) for clinical use in
USA. BMP2 (InfuseTM, Medtronic Sofamor Danek, Inc.) and
BMP7 (OP-1TM, Stryker Biotech) repair injuries by mediating
spinal fusion or fracture healing.244,245
During fracture repair, BMPs are produced by MSCs,
osteoblasts, and chondroblasts, and trigger a cascade of
events, such as proliferation and differentiation of MSCs,
angiogenesis, and synthesis of the ECM.246 BMP-2 acts on
global cellular mobilization and it is also present during the
later stages of osteogenesis and chondrogenesis, whereas
BMP-7 acts on osteogenic differentiation.246 Given that
BMPs are not tissue specific, their localized, targeted, and
controlled delivery is required to prevent any undesired
and uncontrolled bone formation in inadequate tissues of
the body.247
In human clinical treatments, large doses of BMPs (2–
12mg) have been used,248–251 which exceed by far the normal
physiological concentrations of these proteins (18.8–22 pg/
mL)252 in bone defect areas. As an example, the concentra-
tion of BMP-2 approved for application in spine fusion is
1.5mg/mL.251 Therefore, it is clear that the collagen carriers
used in the FDA-approved formulations mentioned above
are less effective in providing structural integrity, effective
mechanotransduction in large nonunion sites, and control
over release kinetics.253 Furthermore, BMP-2 is a well-known
chemoattractant for lymphocytes, monocytes, and macro-
phages and it has also been reported that rapid release of
BMP-2 in high doses can induce transient osteoclast-medi-
ated resorption before new bone formation occurs in meta-
physeal defects.251,254 The role of the carrier on the outcome
of the delivery therapy has been evaluated and the effective
and therapeutic doses change according to the carrier, thus
highlighting its relevant function.255,256
While the current landscape of GFs used for bone re-
generation is dominated by BMPs, a number of other GFs
are being investigated for their potential to regenerate
bone.245 It has been reported that TGF-b1 promotes osteo-
genic differentiation in the early and late stages of
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ectopic bone formation despite its inhibitory effects
in vitro.257 FGF-2 displays a dual role, acting both on the
stimulation of angiogenesis and osteogenesis.111 It is sug-
gested that (FGF/FGF receptor) signaling pathways coor-
dinates a bone anabolic effect by simultaneously activating
Runx2 and BMP-2 pathways.231 The sequential supple-
mentation of FGF-2 followed by BMP-2 tends to enhance
bone phenotype markers.258 While BMP-2 acts mainly on
the osteoblastic differentiation, FGF-2 promotes cell prolif-
eration, increasing the cell population that will be influ-
enced by the action of BMP-2.259
Factors that drive mobilization of BMSCs have been un-
clear, but one of the earliest consequences of a bone fracture
or injury is local tissue hypoxia. Multipotential MSCs are
mobilized into peripheral blood and the Stromal-Derived
Factor-a (SDF-a) is known for its role in stem cell homing,
mobilization of endothelial progenitor cells, and hemato-
poietic stem cells to the injury site.260
Table 1. Growth Factors Roles on Bone and Cartilage Formation and Healing
Growth factor Role on bone formation/healing Role on cartilage formation/healing
BMPs Most osteoinductive GFs223 Induction of Sox9 expression
Promotion of migration, proliferation, and
osteogenic differentiation of MSCs57,221–223
Initiation and regulation of embryonic
development and morphogenesis of cartilage
Influence on skeletal pattern formation.222 Proliferation and maturation of chondrocytes
Strong induction of chondrogenic differentiation
of MSCs by isoform 2
TGF-bs Chemoattractant for osteoprogenitor
cells57,73,221,223
Promotion of collagen, osteonectin, and
osteopontin production221,223
Stimulation of undifferentiated MSCs
proliferation73,222
Inhibition of mature and progenitor osteoclast
cells proliferation221
Inhibition of matrix metalloproteinases, known
for their role on ECM digestion
Stabilization of new blood vessels
Direction of BMSCs toward resorption sites
Induction of Sox9 expression
Initiation of matrix proteins aggrecan and COMP
expression
Enhancement of chondrocyte proliferation
by isoforms 2 and 3
Stimulation of chondrogenic differentiation
of MSCs by isoforms 1 and 3
Inhibition of the activity of MMPs by isoform 1147
Isoform 3 is imperative for Sox9 expression,
but it is not required for continued expression
of chondrogenic markers at later stages
of chondrogenesis
IGF-I Stimulation of osteoprogenitors proliferation73
and bone matrix production221,222
Stimulatory effects on osteoblast activity and
chemotaxis and antiapoptotic effect on
preosteoblasts57
Upregulation of collagen type I
Inflammation mediator
Stimulation of anabolic activity and proliferation
of chondrocytes147,151
Chondrogenic differentiation of MSCs
Stimulation of ECM production151
Protection of ECM from IL-1 and TNF-a-mediated
degradation during cartilage injury147
FGF-2 Stimulation of migration, proliferation, and
differentiation of mature and progenitor
osteoblasts57,73,111,221
Differentiation stage-specific effect
Stimulation of angiogenesis through activation
of capillary endothelial cells and fibroblasts223
Activation of pathways ultimately leading to the
upregulation of Sox9
Promotion of cell proliferation4,147 and inhibition
of chondrogenic differentiation
PDGF Chemotactic and mitogenic effects (precursor
and mature endothelial cells and
inflammatory cells)57,73,111,222,223
Maturation of blood vessels by the recruitment
of SMCs to the endothelial lining
Upregulation of VEGF expression.
Maintenance of hyaline-like cartilage phenotype
Enhancement of chondrocyte proliferation and
proteoglycan synthesis147
VEGF Essential for endochondral bone formation due
to its ability to induce migration and
differentiation of osteoblasts116
Initiatior of angiogenesis. Formation and
maintenance of blood vessels57,111,223
Recruitment of circulating endothelial
progenitor cells and inhibition of endothelial
cells apoptosis111,223
Information was collected from Refs.4,57,73,76,111,116,147,151,221–233
BMSCs, bone marrow mesenchymal stem cells; BMP, bone morphogenetic protein; COMP, cartilage oligomeric matrix protein; ECM,
extracellular matrix; FGF, fibroblast growth factor; GFs, growth factors; IL, interleukin; IGF, insulin growth factor; MMPs, matrix
metalloproteinases; MSCs, mesenchymal stem cells; SMC, smooth muscle cells; TGF, transfoming growth factor; TNF, tumor necrosis factor;
VEGF, vascular endothelial growth factor.
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Cartilage. In cartilage repair, the most investigated GFs
include TGF-b, BMPs, and IGF-I.147,148,261 Further details on
the role of the most significant GFs acting on cartilage can be
found further in Table 1 and Figure 3. Despite the amount of
publications reporting the effect of specific GFs on chon-
drocytes and chondrogenic differentiation of stem cells, little
is known about GFs regulating cartilage wound healing and,
specifically, the spatial and temporal expression of GFs in
acute cartilage wound healing.262 Most of the information
regarding TE of cartilage was provided by the study of
growth plate of long bones. However, it is admitted that the
knowledge of fetal development can provide relevant in-
sights for regenerative medicine purposes as regeneration
partially recapitulates several developmental steps.263,264
In early embryological development, Sox9 is required for
the aggregation of MSCs. Moreover, this transcription factor
is also required for the expression of collagen II and
aggrecan, two of the most important ECM components in
hyaline cartilage.261
Active TGF-b1, 2, and 3 are generally considered to be
potent stimulators of proteoglycans and collagen type II
synthesis.265 During acute cartilage wound healing (Fig. 3B),
TGF-b1 and TGF-b3 are highly expressed, particularly dur-
ing the first 2 weeks upon injury.262 Despite the powerful
ability of TGF-b1 to repair damaged cartilage, high dose of
intra-articular injections of the GF resulted in chemotaxis and
activation of inflammatory cells, promoting fibrosis. Ad-
ditionally, TGF-b1 has been shown to regulate the autocrine/
paracrine axis of IGF-I.266 Hence, drug delivery systems with
fine tuning over dosage and rate of delivery are required to
fulfill the potential of these bioactive agents.267
In fact, intra-articular injections of specific drugs have
failed to produce the desired therapeutical outcomes. The
high reactivity of synovium and rapid efflux of drugs from
the joint cavity have impaired the effect of bioactive agents
injected directly into the articular cartilage.268
Numerous GFs are needed to properly sequence chon-
drogenesis and it is unlikely that any single GF will lead to
complete cartilage repair or affect the arthritic milieu, but
rather a combination in a synergistic approach will be re-
quired.147 There is considerable cross talk between the TGF
and BMP signaling pathways and simultaneous activation of
both seems to promote chondrogenic maturation.227
Combined treatments of TGF-b1 with BMP-2 and IGF-I
have led to the enhancement of glycosaminoglycan deposi-
tion and mechanical properties.175 However, the most
serious limitations of the use of MSCs for chondrogenic
differentiation through the supplementation with bioactive
factors reside on the fact that cell differentiation do not stop
at the prehypertrophic stage.263
Osteochondral interface. Hypertrophic chondrocytes are
the resident cell population identified at the native os-
teochondral interface.206 As described in Figure 3, after dif-
ferentiation and maturation of cells toward the chondrocyte
phenotype, Osterix and Runx2 become upregulated and
chondrocytes achieve their hypertrophic state. At this stage,
collagen type X is highly expressed. The osteochondral in-
terface is also composed by a mineralized and vascularized
matrix, in which angiogenic factors, such as VEGF and FGF-
2, are upregulated.269,270 However, much interest has been
centered on BMPs to promote osteochondral tissue formation
as these molecules have a powerful effect in stimulating both
new bone and cartilage formation.271
In conclusion, natural processes are multifactorial and
skeletal morphogenesis and regeneration are typically driven
by the concomitant action of multiple factors that can work
synergistically on the same process. Release kinetics are
dependent on the type of tissue and defect.210,272
Besides the presentation of the appropriate factor or
combination of factors, the concentration and duration of
function are critical parameters involved in promoting neo-
tissue formation. Concentrations of GFs should be used
within a therapeutic range, whereas crossing the dosage
limits would result either in an inefficient strategy or in the
production of an abnormal tissue.272
FIG. 2. Temporal sequence of growth factors (GFs) and
cytokines expression during bone regeneration. The solid
dash line represents the inflammatory sequence of events,
peaking early upon the injury with high expression of cyto-
kines, such as tumor necrosis factor (TNF)-a, interleukin (IL)-
1, -6, -11, and -18, and angiogenic molecules Angiopoietin-1
(Ang-1) and Ang-2. These molecules are involved in the
stimulation of cell migration, production of cartilaginous
callus, and vascular endothelial growth factor (VEGF) pro-
duction. The square dot line represents the chondrogenic
route that leads to the generation of a cartilaginous callus
peaking between 7 and 14 days after injury. Transfoming
growth factor (TGF)-b1 and Growth differentiation factor-8
(GDF-8) act early in this step, with other isoforms responsible
for chondrogenesis and endochondral ossification peaking
later in the cycle. The long dash double dot line represents the
osteogenic sequence of molecules acting on the formation of a
bony callus. Simultaneously to the expression of chondro-
genic markers, bone morphogenetic protein (BMP)-2, BMP-7,
and stromal cell-derived factor-a (SDF-a) are responsible for
inducing the migration of mesenchymal stem cells (MSCs)
with fibroblast growth factor (FGF)-2 stimulating their pro-
liferation. As callus chondrocytes proliferate, they become
hypertrophic and express high levels of VEGF, promoting the
invasion of blood vessels, leading to the tissue vasculariza-
tion. During this step, TNF-a initiates chondrocyte apoptosis
and promotes the recruitment of MSCs with osteogenic
potential. Moreover, this cytokine is also involved in bone
remodeling, the last step in which the hard callus undergoes a
resorptive phase to form the typical lamellar bone structure
with a central medullar cavity.201–203
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Controlled Release Strategies: The Need
for Spatiotemporal Control
The delivery of multiple GFs has been pursued through
application of different methodologies, making use of the
great versatility of delivery systems developed over the last
decades. However, biological mechanisms of tissue regen-
eration are more complex and, thus, require more than a
particular temporal sequence of therapeutic agents, with
some regenerative tasks demanding tight coordination of the
spatial and temporal presentation of multiple factors.219
GF signaling in tissue healing involves precise regulation
of the concentration, temporal gradient, and spatial gradient
of factors, which ultimately determines the outcome of the
regenerative therapy.124 Controlling the location of release
can create concentration gradients by diffusion of the factors
from the release site.272 The osteochondral interface is a
paramount example of this scenario. The regulation of con-
centration and delivery rates is also particularly relevant as a
suboptimal delivery system does not exploit the full poten-
tial of the released bioactive factor, thus requiring higher
dosages to provide the desired effect.254
Systems releasing drugs acting synergistically provide a
highly inductive therapeutic option, replicating more accu-
rately developmental osteogeonic and chondrogenic cas-
cades, which will ultimately result in a superior clinical
performance using considerably reduced doses of GFs.
However, this will be achieved at the cost of greatly increased
complexity.273 Some of the materials used to produce the
carriers for GFs may provide additional favorable properties
by themselves, such as calcium phosphates or other ions for
bone regeneration, which might not be enhanced by the ad-
dition of specific bioactive agents.274 The combination of
stimulus is not straightforward and the outcomes of the
combination are most of the times unexpected. Hierarchical
systems,275–277 multiple layer systems,278,279 and intelligent
hydrogels280,281 have been developed aiming for the simul-
taneous and/or sequential release of multiple signaling
molecules.
The spatial organization of the GFs in the matrix is critical
because the retention of the molecular bioactivity is also
affected by several parameters, including interactions be-
tween the biomaterial and the GF, the influence of pH and
temperature and porosity.207,282
FIG. 3. (A) Chondrogenic differentiation of MSCs, which involves three main stages influenced mainly by the Sox family
transcription factors, followed by the ossification process. Once chondrocytes reach their mature phenotypic state, osteogenic
transcription factors Osterix and Runx 2 are expressed and chondrocytes evolve to a hypertrophic state. Different GFs are
expressed by cells, depending on their differentiation state. BMP-2 is expressed throughout the process, while TGF-b family is
highly expressed during the MSCs condensation step. The mechanism here described occurs in the growth plate of long
bones and it is responsible for the endochondralossification for bone turn-over. Adapted from 236,243 (B). Cartilage layers
expressing TGF-b1 and TGF-b3 increased between day 1 and 3 and TGF-b1 maintained approximately those levels until day
14. An increase of insulin growth factor (IGF)-I and FGF-2 was observed between day 3 and 7. IGF-I, FGF-2, and TGF-b3
reached a new peak level at day 7 and showed gradual decrease afterward. At day 28, GF expression returned to basal levels.
Color images available online at www.liebertpub.com/teb
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Spatial gradients of factors in scaffolds can be controlled
by varying the positioning of polymer vehicles, immobilizing
ligands on polymer networks to attract target cell popula-
tions, or designing delivery systems to provide spatially
distinct cues.124 Current knowledge of the signals within the
microenvironment that regulate cell fate has led to the de-
velopment of increasingly sophisticated constructs. Scaffolds
with precisely controlled architectures regulating spatio-
temporal release of GFs and morphogens and responding
dynamically to environmental cues have been increasingly
developed.283
Spatial patterns in tissues are controlled by both the ar-
chitectural features of the ECM and concentration profiles
and gradients of diffusible bioactive factors.284 The ability to
combine topographical and biochemical cues within a single
scaffold presents a valuable opportunity to evaluate their
synergistic impact.285
Angiogenesis is paramount of the relevance of a temporal
sequence of bioactive factors expression. Certain factors
initiate angiogenesis, while others induce maturation of
newly formed vessels.286 Later on, a third group of mole-
cules act on the maintenance of the integrity of the estab-
lished vasculature.287 If the appropriate presence and
sequence of bioactive factors are not achieved, poor vascu-
larization occurs.283
Scaffolds can perform the dual roles of biomechanical and
biochemical support by presenting the appropriate media-
tors to the surrounding tissue. The ultimate goal is to de-
velop a multifunctional support performing two main roles:
(1) acting as a temporary structure for cell attachment and
colonization; (2) acting as a delivery platform for multiple
GFs to stimulate tissue regeneration.
Many techniques have been developed to regulate the
kinetics and distribution of soluble factors, including multi-
ple levels of encapsulation and noncovalent bonding of
bioactive factors to peptides with a range of dissociation
constants mimicking ECM immobilization of GFs.283 One of
the most used approaches involves the use of the scaffold as
a controlled release platform by the simple dispersion of
bioactive agents in the matrix or via immobilization to the
scaffold by electrostatic interactions or covalent bonding.284
These monolithic scaffolds, even when combined with GFs
and cells, are still far from leading to successful tissue re-
construction in clinical settings, mainly due to the limited
control exerted over biodegradation and drug delivery.288
Incorporation of GFs into preformed scaffolds has the
advantage that the optimized conditions for scaffold pro-
cessing are not substantially affected by the presence of
proteins. Moreover, the biological activity of the protein can
be preserved.43 However, typically, only small amounts of
proteins can be attached and their release profile becomes
unpredictable. Therefore, scaffold bioactivation is increas-
ingly being accomplished through the incorporation of pre-
formed GF-loaded delivery systems, such as polymeric
particles instead of through direct incorporation, as demon-
strated in Figure 4.43
Microspheres/nanospheres have been widely used as
tools for controlled drug delivery due to their small dimen-
sions and the corresponding high surface area, high drug
loading efficiency, high reactivity toward surrounding tis-
sues, and high diffusibility and mobility.288 Moreover, their
size allows them to respond quickly to environmental stim-
ulus. Generally, microspheres can be processed into macro-
scopic constructs as (1) a dispersed phase surrounded by a
FIG. 4. Strategies to promote the release of multiple bioactive factors from a matrix. Molecules can be physically dispersed
inside the matrix by dispersion of the factor before the carrier processing or by impregnation postcarrier preparation (A).
Typically, this leads to uncontrolled and fast drug delivery kinetics. One strategy to incorporate multiple bioactive signaling
molecules into a matrix is developing hierarchical multiscale systems by the incorporation of nano- and microscale carriers
into the constructs. The entrapment of the drugs in these carriers might offer an enhanced protection for degradation and
high control over the delivery kinetics. These particulate carriers can be tailored to release bioactive factors in specific kinetics,
allowing either a simultaneous (B) or sequential (C) presentation of signaling molecules. The spatiotemporal controlled
release profiles can also be achieved through the conjugation of the drugs with ligands. Bioactive factors or particulate
carriers can be covalently bound to the matrix, resulting in a more controlled mechanism of incorporation (D). Affinity-bound
systems such as binding through heparin domains are a common approach. These mechanisms can be combined to design
even more complex systems. Moreover, the development of multiscale systems is highly promising as nanoparticles can be
incorporated inside microparticles within the constructs (E), promoting dual or multiple release systems with distinct de-
livery rates. The development of gradients of bioactive factors (F) is also an increasingly used approach. Besides promoting
cell migration and inducing specific cell responses according to the concentration gradients, these systems allow a precise
tailoring over the availability of the desired factor, following a biomimetic approach. Color images available online at
www.liebertpub.com/teb
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continuous matrix289,290; or as (2) building blocks to establish
integral scaffolds without a surrounding matrix by a bottom-
up approach.288,291,292
When included in a scaffold, they can also act as rein-
forcement phase, providing higher mechanical strength and
protecting the drug from in vivo degradation.288 Moreover,
the incorporation of preformed delivery systems allows the
combination of carriers with different release rates, entrap-
ping different drugs, thus showing the potential for tailoring
the availability of multiple signaling molecules at different
preprogrammed rates (Fig. 4).288–290
Some of the advantages of entrapping preformed micro-
particulate delivery systems in TE constructs include the
extra protection of the entrapped drugs to the physical and
chemical adversities inherent to scaffold processing tech-
niques and the fact that it avoids a new scaffold design for
optimization of processing parameters.43 Delivery from
scaffolds loaded with particulate carriers allows to retain the
bioactive factor for an extended time, overcoming the dis-
advantages of the direct immobilization of GF in scaffolds
that have poor control over release rates due to an open pore
structure and exposure of the drug to the medium.43,293
When molded into 3D constructs, the drug delivery capacity
of the carriers is coupled with the structural support pro-
vided by the scaffold. Although in these cases the release is
mostly controlled by the properties of the carriers, the en-
trapment within the hydrogel/scaffold also influences the
delivery.272
The integration of controlled release systems such as
micro- and nanoparticles within scaffolds leads to the
development of hierarchically organized and multifunc-
tional constructs with enhanced ability to control and guide
neotissue formation through the recapitulation of spatial and
temporal microenvironments presented by the ECM.284,294
However, it should be noted that the addition of those car-
riers by themselves into the scaffolding structure might have
a surprisingly large impact on the cell response and should
be considered when designing these structures.295
Following a bottom-up approach, some studies have
shown the possibility of designing highly defined geometries
by the assembly of micro- and nanocarriers.296,297 The bot-
tom-up approach for the generation of new materials has
become increasingly attractive for developing novel engi-
neering scaffolds with precise combination of cells, biomol-
ecules, and synthetic biomaterials. These particles act as
building blocks and can assemble by random packing, while
simultaneously entrapping signaling biomolecules, bioactive
minerals, or cells seeded on the surface.288 However, one
drawback is their poor integrity resulting from weak parti-
cle interactions. To preserve the agglomeration of these
formulations, glues and crosslinkers have been used or even
multilayered films prepared by layer by layer of polyelec-
trolytes.298 Moreover, thermal fusion of the particles into in-
tegrated scaffolds has also been used as an alternative.
Nanoparticles can also assemble by an electrostatic interaction
between oppositely charged spheres—colloidal gels.299–301
Summary
There are several GFs and other bioactive molecules in-
volved in the process of bone, cartilage, and osteochondral
interface regeneration. These signaling molecules are pre-
sented in situ with a specific dosage, spatial distribution, and
temporal sequence and TE strategies are increasingly trying
to mimic these native healing cascades. As expected, this is
not an easy task and mixed results have been obtained in this
field. Part II of this review will report some of the most
relevant studies on the use of single, dual, and multiple GF
delivery in direct and indirect approaches for bone, cartilage,
and osteochondral TE strategies.
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